Discontinued ProductUnfortunately Methimepip dihydrobromide (Cat. No. 2947) has been withdrawn from sale for commercial reasons.
Extremely selective histamine H3 receptor agonist (pKi values are 9.0, 5.7, < 5.0 and < 5.0 for hH3, hH4, hH1 and hH2 receptors respectively). Potently inhibits EFS-evoked contractions of guinea pig ileum (pD2 = 8.26).
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
References are publications that support the products' biological activity.
Kitbunnadaj et al (2005) N-substituted piperidinyl alkyl imidazoles: discovery of methimepip as a potent and selective histamine H3 receptor agonist. J.Med.Chem. 48 2100 PMID: 15771452
View Related Products by Product Action
Keywords: Methimepip dihydrobromide, supplier, selective, H3, agonists, Receptors, Histamine, histaminergic, Histamine, H3, Receptors, Histamine, H3, Receptors, Tocris Bioscience
Citations for Methimepip dihydrobromide
Citations are publications that use Tocris products.
Currently there are no citations for Methimepip dihydrobromide.
Reviews for Methimepip dihydrobromide
There are currently no reviews for this product. Be the first to review Methimepip dihydrobromide and earn rewards!
Have you used Methimepip dihydrobromide?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.